File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study

TitleEffects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study
Authors
Issue Date2017
PublisherWiley-Blackwell. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2036
Citation
Alimentary Pharmacology and Therapeutics, 2017, v. 45 n. 4, p. 501-509 How to Cite?
AbstractBackground: The temporal relationship between nucleoside analogue therapy for chronic hepatitis B (CHB) and liver cancer development has not been evaluated at a population level. Aim: To investigate the impact of nucleoside analogue prescription on liver cancer incidence in a CHB‐prevalent region. Methods: We obtained territory‐wide nucleoside analogue prescription data from 1999, when nucleoside analogue was first available in Hong Kong, to 2012 and the population‐based liver cancer incidence data from 1990 to 2012. We compared the liver cancer incidences from 1990 to 1998 and 1999 to 2012 with adjustment for local hepatitis B surface antigen seroprevalence. Results: Nucleoside analogue prescription patient headcount increased from 2006 per year in 1999 to 26 411 in 2012. Prescription volume in 2012 was highest among 55–64 years (30.3%), higher than 65–74 years (13.0%) and ≥75 years (5.8%). Age‐standardised liver cancer incidence 1999–2012 decreased by 1.88%/year (95% CI 3.34% to 0.42%/year). NA therapy was associated with decline in age‐adjusted liver cancer incidence (2.7 per 100 000 persons, P < 0.001, 95% CI 1.4–4.0 per 100 000 persons). Fifty‐five to sixty‐four years age group had the most significant decline (men: 24.0 per 100 000 persons, P = 0.001, 95% CI 11.4–36.6 per 100 000 persons; women: 8.5 per 100 000 persons, P = 0.009, 95% CI 2.3–14.6 per 100 000 persons). No significant association was noted in age groups 65–74 years and ≥75 years (both P > 0.05). Conclusions: Nucleoside analogue prescription was associated with a reduction of overall liver cancer incidence in a CHB‐prevalent region. The lack of association among individuals of ≥65 years was consistent with the low nucleoside analogue prescription volume in elderly patients, mitigating the impact of CHB treatment on liver cancer.
Persistent Identifierhttp://hdl.handle.net/10722/237727
ISSN
2023 Impact Factor: 6.6
2023 SCImago Journal Rankings: 2.794
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSeto, WKW-
dc.contributor.authorLau, EHY-
dc.contributor.authorWu, JTK-
dc.contributor.authorHung, FNI-
dc.contributor.authorLeung, WK-
dc.contributor.authorCheung, KSM-
dc.contributor.authorFung, JYY-
dc.contributor.authorLai, CL-
dc.contributor.authorYuen, RMF-
dc.date.accessioned2017-01-20T02:27:32Z-
dc.date.available2017-01-20T02:27:32Z-
dc.date.issued2017-
dc.identifier.citationAlimentary Pharmacology and Therapeutics, 2017, v. 45 n. 4, p. 501-509-
dc.identifier.issn0269-2813-
dc.identifier.urihttp://hdl.handle.net/10722/237727-
dc.description.abstractBackground: The temporal relationship between nucleoside analogue therapy for chronic hepatitis B (CHB) and liver cancer development has not been evaluated at a population level. Aim: To investigate the impact of nucleoside analogue prescription on liver cancer incidence in a CHB‐prevalent region. Methods: We obtained territory‐wide nucleoside analogue prescription data from 1999, when nucleoside analogue was first available in Hong Kong, to 2012 and the population‐based liver cancer incidence data from 1990 to 2012. We compared the liver cancer incidences from 1990 to 1998 and 1999 to 2012 with adjustment for local hepatitis B surface antigen seroprevalence. Results: Nucleoside analogue prescription patient headcount increased from 2006 per year in 1999 to 26 411 in 2012. Prescription volume in 2012 was highest among 55–64 years (30.3%), higher than 65–74 years (13.0%) and ≥75 years (5.8%). Age‐standardised liver cancer incidence 1999–2012 decreased by 1.88%/year (95% CI 3.34% to 0.42%/year). NA therapy was associated with decline in age‐adjusted liver cancer incidence (2.7 per 100 000 persons, P < 0.001, 95% CI 1.4–4.0 per 100 000 persons). Fifty‐five to sixty‐four years age group had the most significant decline (men: 24.0 per 100 000 persons, P = 0.001, 95% CI 11.4–36.6 per 100 000 persons; women: 8.5 per 100 000 persons, P = 0.009, 95% CI 2.3–14.6 per 100 000 persons). No significant association was noted in age groups 65–74 years and ≥75 years (both P > 0.05). Conclusions: Nucleoside analogue prescription was associated with a reduction of overall liver cancer incidence in a CHB‐prevalent region. The lack of association among individuals of ≥65 years was consistent with the low nucleoside analogue prescription volume in elderly patients, mitigating the impact of CHB treatment on liver cancer.-
dc.languageeng-
dc.publisherWiley-Blackwell. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2036-
dc.relation.ispartofAlimentary Pharmacology and Therapeutics-
dc.titleEffects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study-
dc.typeArticle-
dc.identifier.emailSeto, WKW: wkseto2@hku.hk-
dc.identifier.emailLau, EHY: ehylau@hku.hk-
dc.identifier.emailWu, JTK: joewu@hku.hk-
dc.identifier.emailHung, FNI: ivanhung@hkucc.hku.hk-
dc.identifier.emailLeung, WK: hku75407@hku.hk-
dc.identifier.emailCheung, KSM: cks634@hku.hk-
dc.identifier.emailFung, JYY: jfung@hkucc.hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hku.hk-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authoritySeto, WKW=rp01659-
dc.identifier.authorityLau, EHY=rp01349-
dc.identifier.authorityWu, JTK=rp00517-
dc.identifier.authorityHung, FNI=rp00508-
dc.identifier.authorityLeung, WK=rp01479-
dc.identifier.authorityCheung, KSM=rp02532-
dc.identifier.authorityFung, JYY=rp00518-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authorityYuen, RMF=rp00479-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/apt.13895-
dc.identifier.pmid27976416-
dc.identifier.scopuseid_2-s2.0-85007201363-
dc.identifier.hkuros270980-
dc.identifier.volume45-
dc.identifier.issue4-
dc.identifier.spage501-
dc.identifier.epage509-
dc.identifier.isiWOS:000393790200002-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl0269-2813-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats